ISRCTN87831050进行中（未招募）1 期
A phase-1b dose escalation study to assess the effect of NG11-2 on radiation induced oral mucositis in patients with head & neck cancer
VasoDynamics Ltd0 个研究点目标入组 32 人开始时间: 2023年2月13日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 32
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Male or female head and neck cancer patients scheduled for radiotherapy, aged 18 or over on day of signing informed consent;
- •2. Histologically confirmed head and neck cancer with or without previous resective surgery, having not been previously treated with radiation therapy
- •3. Scheduled to receive a mean radiation dose of no less than 30 Gy on either (a) Extended Oral Cavity, or (b) Buccal Mucosa, or (c) Lips, according to CT-based delineation of Organ-At-Risk (OAR) Guideline, with or without concurrent chemotherapy (Section 13.8 for guidance);
- •4. Rendered dentally fit for radiotherapy;
- •5. Have a Performance Status >60 on the Karnofsy scale
- •6. No evidence of active systemic infections at the time of screening;
- •7. No oral fungal infection by visual examination or swab test;
- •8. Body Mass Index >=18.5 kg/m²
- •9. Normalcy of diet evaluated with the Performance Status Scale for Head and Neck cancer patients (PSSHN) >=30;
- •10. Ability to retain and swill liquid inside the oral cavity for at least 90 seconds;
- •11. Female patients of childbearing potential must have a negative urine or serum pregnancy test during the 2 week Screening period
- •12. Provide written informed consent for the trial.
- •13. Consent to utilize medically acceptable methods of contraception throughout the study period if of child-bearing potential;
- •14. Be able to comply with protocol procedures (such as Oral Mucositis assessment and swish/spit) and study schedule
排除标准
- •1. Tumour of the larynx
- •2. Mentally or legally incapacitated, in the opinion of the PI, which could interfere with the ability of the patient to understand or adhere to the requirements of the study;
- •3. Open or unhealed non-cancerous wounds or ulcers in the oral cavity;
- •4. WHO Oral Mucositis grade of 2 or more
- •5. Uncontrolled Hypertension, defined as blood pressure in adults >150/100mm Hg at screening;
- •6. A known clinically significant abnormal ECG, such as arrhythmia and active ischemia,within 6 months prior to treatment;
- •7. Xerostomia or hyposalivation;
- •8. Known allergy or intolerance to sympathomimetic drugs (e.g., pseudoephedrine, epinephrine), alcohol, or any NG11-2 excipient;
- •9. Receiving monoamine oxidase (MAO) inhibitors or antidepressants (triptyline or imipramine types); Use of MAO inhibitor in the 14 days prior to treatment, such as isocarboxazid, linezolid, methylene blue injection, phenelzine, rasagiline, selegiline, or tranylcypromine;
- •10. History or current evidence of clinically significant laboratory abnormality or any disease condition that might confound the results of the study, or interfere with the patient’s participation for the full duration of the study
- •11. Current participation in any other oral mucositis studies or completion/ withdrawal from any other oral mucositis studies within the last 3 months
- •12. Patient is, at the time of signing informed consent, a regular user of any illicit drugs, which would interfere with cooperation with the requirements of the trial;
- •13. Patient is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the study;
- •14. Any other condition which, in the opinion of the Investigator, means that the patient is not a good candidate for study enrolment
研究者
相似试验
进行中（未招募）
不适用
Phase I/II dose-escalation study of the investigational trifunctional bispecific anti-CD20 x anti-CD3 antibody FBTA05 in combination with donor lymphocyte infusion (DLI) in patients with CD20 positive chronic lymphocytic leukemia (CLL), low and high grade non-Hodgkin´s lymphoma (NHL) after allogeneic stem cell transplantion. - STP-LYM-01-V01EUCTR2009-014641-88-DEMedizinische Fakultaet der Technischen Universitaet Muenchen
进行中（未招募）
不适用
Phase I/II dose-escalation study of the investigational trifunctional bispecific anti-CD20 x anti-CD3 antibody FBTA05 in relapsed or refractory chronic lymphocytic leukemiarelapsed or refractory Chronic Lymphocytic LeukemiaMedDRA version: 9.1Level: LLTClassification code 10008976Term: Chronic lymphocytic leukemiaEUCTR2006-006694-24-DEFresenius Biotech GmbH
招募中
1 期
Tucatinib plus trastuzumab and oxaliplatin-based chemotherapy or pembrolizumab-containing combinations for HER2+ gastrointestinal cancersColorectal adenocarcinoma (CRC), Gastric adenocarcinoma, GEJ adenocarcinoma,JPRN-jRCT2031220143Mayor JoAl40
招募中
不适用
A Phase I clinical study to evaluate the safety and efficacy of allogenic adipose-derived stem cells in the patients with Crohn's fiatula.Symptoms, signs and abnormal clinical and laboratory findings, NECKCT0000188Anterogen6
尚未招募
1 期
VSSPs in renal carcinoma.VaccinesInjections, SubcutaneousCarcinoma, Renal CellAdenocarcinomaCarcinomaNeoplasms, Glandular and EpithelialKidney NeoplasmsUrologic NeoplasmsUrogenital NeoplasmsKidney DiseasesUrologic DiseasesUrogenital Diseasesmetastatic renal carcinomaAdjuvants, ImmunologicImmunomodulating AgentsRPCEC00000425Center of Molecular Immunology (CIM)70